The Effective And Safety Of Linaclotide On Constipation Predominant Irritable Bowel Syndrome:a Meta-analysis

AIM:To perform a meta-analysis to determine the efficacy and the safety of linaclotide, compared with placebo, for patients with constipation predominant irritable bowel syndrome (C-IBS).METHODS:CNKI, CBM, wanfang, VIP, PubMed, EMBASE, clinical trials.gov and the Cochrane library were searched for randomized, placebo controlled trials examining the effect of linaclotide in adults with C-IBS. Dichotomous results were pooled by using the software of stata 13.0 and RevMan v.5.2 to yield a relative risk (RR),95% confidence intervals (CIs).RESULTS:The search identified five randomized controlled trials of linaclotide in patients with C-IBS published in four papers. The primary end point were:the RR (95%CI) of the responder of worst abdominal pains (RR= 1.581,95%CI= 1.018,2.456); the responder of complete spontaneous bowel movements (CSBMs) (RR=3.213,95%CI= 2.412,4.280); the responder of abdominal bloating (RR=1.535,95%CI=1.132,2.081); the responder of stool consistency(RR=1.323,95%CI=1.243,1.408); the responder of IBS Quality-of-life (RR= 1.38, 95%CI=1.09-1.74). Diarrhea was the most frequently adverse event (AE) in the group of linaclotide than placebo.CONCLUSION:On the basis of our study, linaclotide improves bowel function and reduces abdominal pain and the quality-of-life of C-IBS, compared with placebo.